Product Overview
Ozagrel (CAS: 82571-53-7), a potent thromboxane A2 synthase inhibitor, is an antithrombotic agent with the molecular formula C₁₃H₁₂N₂O₂ and molecular weight 228.25 13. It selectively inhibits thromboxane A2 synthesis, reducing platelet aggregation and vasoconstriction, making it effective in treating cerebral thrombosis and acute ischemic stroke 13. Available as a white crystalline powder, it is widely used in clinical and research settings for thrombosis-related disorders 14.
✨ Key Advantages
✅ High Purity: ≥99% (HPLC/GC verified), meeting pharmaceutical-grade standards 12.
✅ Selective Action: IC₅₀ of 4 nM against thromboxane A2 synthase, ensuring targeted efficacy 3.
✅ Stability: Stable under 2–8°C storage or dry, sealed conditions 12.
🔬 Application Fields
Clinical Medicine: Treatment of cerebral thrombosis and ischemic cerebrovascular diseases 13.
Research: Study of platelet aggregation mechanisms and thromboxane-related pathologies 35.
Pharmaceutical Synthesis: Intermediate for antithrombotic drug development 12.
📜 Quality Certifications
Produced under GMP-compliant protocols, adhering to USP/EP standards for export and research 25.
Rigorous testing via HPLC, NMR, and mass spectrometry 56.
Complies with MSDS guidelines for safe handling and transport 12.
📈 Market Insights
The global antithrombotic drug market is projected to grow at CAGR 6.8% by 2030, driven by increasing cardiovascular disease prevalence 36. Ozagrel’s role in managing acute thrombotic events positions it as a critical therapeutic agent 13.
China
